



Discard the white transition adapter and connect the purple fitting from the tubing set to the clear RELiZORB inlet, and then connect RELiZORB to the ENFit extension set.

For instructions for use, including detailed set up instructions and safety information, please visit relizorb.com

Helpful ENFit tips:

The Global Enteral Device Supplier Association (GEDSA) and The Oley Foundation recommend the following guidance for using ENFit supplies:

- When priming your pump, stop priming before fluid reaches the end of the tube.¹ If any formula drips into the ENFit connector, wipe off any excess residue with gauze or tissue.²
- Keeping ENFit connectors clean and dry will prevent connections from becoming stuck together.²
- Be careful not to overtighten the ENFit connector.²
- For more information on keeping your ENFit connectors clean, visit stayconnected.org/ENFit-cleaning-procedures-all-tubes

After connecting your RELiZORB cartridge to the primed feeding tube, manually prime formula through the RELiZORB cartridge up to the outlet, then connect the outlet to the patient extension set.³

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula. RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELiZORB.

Support is just a phone call away at **1-844-632-9271**

or email: info@relizorbsupport.com

relizorb.com

RELIZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula. RELIZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELIZORB.

For instructions for use, including detailed set up instructions and safety information, please visit relizorb.com

References: **1.** Global Enteral Device Supplier Association (GEDSA). <https://stayconnected.org/ENFit-cleaning-procedures-all-tubes>. Accessed February 23, 2023. **2.** Oley Foundation. Lifeline Letter. September/October 2022:7-9. **3.** RELIZORB. Instructions for Use. Alcresta Therapeutics;2020.



130 Turner Street
Waltham, MA 02453

ENFit® is a registered trademark of GEDSA. RELIZORB, iLipase, the Alcresta capstone, and Alcresta Therapeutics are registered trademarks of Alcresta Therapeutics, Inc. Patents: <http://www.alcresta.com/patents>

©2023 Alcresta Therapeutics, Inc. All rights reserved. REL2023-1341